---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-218150"
form_type: "8-K"
ticker: "ALKS"
cik: "0001520262"
company_name: "Alkermes plc."
filed_at: "2026-05-12T11:07:58+00:00"
generated_at: "2026-05-12T11:10:51.364148+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# LUMRYZ meets all primary, key secondary endpoints in Phase 3 idiopathic hypersomnia study

## Summary
- Primary endpoint ESS showed statistically significant improvement vs placebo (p<0.0001).
- Key secondary endpoints PGI-C and IHSS also met with p<0.0001.
- Safety profile consistent with known LUMRYZ safety; common AEs included nausea, headache.
- Alkermes plans to file sNDA with FDA by end of 2026 for IH indication.
- Settlement agreement restricts marketing of LUMRYZ for IH until March 1, 2028.

## SEC filing metadata
- accession: 0001193125-26-218150
- form_type: 8-K
- ticker: ALKS
- cik: 0001520262
- company_name: Alkermes plc.
- filed_at: 2026-05-12T11:07:58+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1520262/000119312526218150/0001193125-26-218150-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1520262/000119312526218150/alks-20260512.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-218150
- JSON: https://secwatch.observer/filing/0001193125-26-218150.json
- Plain text: https://secwatch.observer/filing/0001193125-26-218150.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.